ArticleOncoimmunology
CCR5 status and metastatic progression in colorectal cancer.
Open access · goldAbstract read
In one paragraph
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 44 citations in OpenAlex.
- A silence catalyst: CCL5-mediated intercellular communication in cancer.Archives of toxicology · 2025Review
- Regulation and Function of Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): The Role of the SRIF System in Macrophage Regulation.International journal of molecular sciences · 2025Review
- The Role of Macrophages in Various Types of Tumors and the Possibility of Their Use as Targets for Antitumor Therapy.Cancers · 2025Review
- Key genes associated with brain metastasis in non-small cell lung cancer: novel insights from bioinformatics analysis.Frontiers in bioinformatics · 2025Article
- Immune microenvironment regulation and clinical immunotherapy strategies of metastatic liver cancer.Frontiers in immunology · 2025Review
- Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies.Molecular cancer · 2024Review
- Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review.Cancers · 2024Review
- Signaling pathways in colorectal cancer implications for the target therapies.Molecular biomedicine · 2024Review
- CCR5 and CCL5 in metastatic colorectal cancer.Journal for immunotherapy of cancer · 2024Article
- Article
- Review
- Astragalus mongholicus Bunge-Curcuma aromatica Salisb. suppresses growth and metastasis of colorectal cancer cells by inhibiting M2 macrophage polarization via a Sp1/ZFAS1/miR-153-3p/CCR5 regulatory axis.Cell biology and toxicology · 2022Article
- Non-coding RNAs and ferroptosis: potential implications for cancer therapy.Cell death and differentiation · 2022Review
- miR-149-3p Is a Potential Prognosis Biomarker and Correlated with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.International journal of endocrinology · 2022Article
- CCL5/CCR5 axis in human diseases and related treatments.Genes & diseases · 2022Review
- A promising research direction for colorectal cancer immunotherapy: The regulatory mechanism of CCL5 in colorectal cancer.Frontiers in oncology · 2022Review
- Inflammation and tumor progression: signaling pathways and targeted intervention.Signal transduction and targeted therapy · 2021Article
- Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy.Breast cancer research : BCR · 2021Article
- Review
- C-C chemokine receptor 5 signaling contributes to cardiac remodeling and dysfunction under pressure overload.Molecular medicine reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 3 institutions in 1 country.
Meggy Suarez-CarmonaDepartment of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-8892-1546
Pornpimol ChaorentongClinical Cooperation Unit Applied Tumor Immunity, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.
Jakob Nikolas KatherMedical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.ORCID 0000-0002-3730-5348
Rebecca RothenheberMedical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Azaz AhmedMedical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Anna BerthelMedical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Anita HeinzelmannMedical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Rodrigo MoraledaMedical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Nektarios A ValousClinical Cooperation Unit Applied Tumor Immunity, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0002-4014-2404
Zeynep KosalogluClinical Cooperation Unit Applied Tumor Immunity, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0003-0961-5055
Rosa EurichMedical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Jana WolfMedical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Silke Grauling-HalamaDepartment of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Michael HundemerDepartment of Hematology, University Hospital Heidelberg, Heidelberg, Germany.
Felix LasitschkaInstitute for Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Fee KluppDepartment of Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Christoph KahlertDepartment of Surgery, University Hospital Dresden, Dresden, Germany.
Alexis UlrichDepartment of Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Martin SchneiderDepartment of Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Christine FalkInstitute of Transplant Immunology, Integrated Research and Treatment Center Transplantation, Hannover Medical School Hannover, Hanover, Germany.
Dirk JägerMedical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Inka ZoernigMedical oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Niels HalamaDepartment of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-0344-6027
Heidelberg University · DEGerman Cancer Research Center · DEMedizinische Hochschule Hannover · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple reports have highlighted the importance of the local immunological cellular composition (
Indexed as
CCL5CCR5colorectal cancerdisease free survivalimmune checkpointimmunotherapymacrophagesmicroenvironmentT cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.